MPNs

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer.

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, but at the same time, America’s medical community should work harder to avoid the screen’s potential pitfalls.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.

An investigator reported at the 55th annual meeting of the American Society of Hematology (ASH) that imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

The phase III JAKARTA trial of SAR302503 for myelofibrosis met its primary endpoint in both dose groups, as reported by Sanofi.

Tal Zaks, MD, PhD, explains the mechanism of action of SAR302503, a TKI being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.

An investigational, selective JAK2 inhibitor known as SAR302503 reduced spleen size in patients with myelofibrosis, according to phase II data presented at the 2012 American Society of Hematology Annual Meeting and Exposition.